NextCure, Inc. (NXTC)

Revance Therapeutics Statistics

Total Valuation

NextCure has a market cap or net worth of $13.09 million. The enterprise value is -$36.93 million.

Market Cap	13.09M
Enterprise Value	-36.93M

Important Dates

The next estimated earnings date is Tuesday, August 12, 2025, after market close.

Earnings Date	Aug 12, 2025
Ex-Dividend Date	n/a

Share Statistics

NextCure has 2.68 million shares outstanding. The number of shares has increased by 0.44% in one year.

Current Share Class	2.68M
Shares Outstanding	2.68M
Shares Change (YoY)	+0.44%
Shares Change (QoQ)	+0.00%
Owned by Insiders (%)	1.65%
Owned by Institutions (%)	25.97%
Float	2.06M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.20
P/TBV Ratio	0.23
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 10.26, with a Debt / Equity ratio of 0.10.

Current Ratio	10.26
Quick Ratio	9.78
Debt / Equity	0.10
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -63.94% and return on invested capital (ROIC) is -39.67%.

Return on Equity (ROE)	-63.94%
Return on Assets (ROA)	-36.39%
Return on Invested Capital (ROIC)	-39.67%
Return on Capital Employed (ROCE)	-86.43%
Revenue Per Employee	n/a
Profits Per Employee	-$1.15M
Employee Count	43
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -74.85% in the last 52 weeks. The beta is 1.26, so NextCure's price volatility has been higher than the market average.

Beta (5Y)	1.26
52-Week Price Change	-74.85%
50-Day Moving Average	5.63
200-Day Moving Average	8.89
Relative Strength Index (RSI)	43.77
Average Volume (20 Days)	324,595

Short Selling Information

The latest short interest is 27,786, so 1.04% of the outstanding shares have been sold short.

Short Interest	27,786
Short Previous Month	300,175
Short % of Shares Out	1.04%
Short % of Float	1.35%
Short Ratio (days to cover)	0.91

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-53.07M
Pretax Income	-61.28M
Net Income	-49.52M
EBITDA	-50.34M
EBIT	-53.07M
Earnings Per Share (EPS)	-$21.23

Balance Sheet

The company has $55.86 million in cash and $5.84 million in debt, giving a net cash position of $50.02 million or $18.69 per share.

Cash & Cash Equivalents	55.86M
Total Debt	5.84M
Net Cash	50.02M
Net Cash Per Share	$18.69
Equity (Book Value)	55.86M
Book Value Per Share	23.93
Working Capital	53.16M

Cash Flow

In the last 12 months, operating cash flow was -$41.19 million and capital expenditures -$437,000, giving a free cash flow of -$41.63 million.

Operating Cash Flow	-41.19M
Capital Expenditures	-437,000
Free Cash Flow	-41.63M
FCF Per Share	-$15.56

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

NextCure does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.44%
Shareholder Yield	-0.44%
Earnings Yield	-378.43%
FCF Yield	-318.12%

Analyst Forecast

The average price target for NextCure is $33.00, which is 549.61% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$33.00
Price Target Difference	549.61%
Analyst Consensus	Strong Buy
Analyst Count	3
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	-53.48%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on July 14, 2025. It was a reverse split with a ratio of 1:12.

Last Split Date	Jul 14, 2025
Split Type	Reverse
Split Ratio	1:12

Scores

Altman Z-Score	n/a
Piotroski F-Score	1